Should the Cure for Cancer Cost the Same in California and Calcutta?

Charles L. Hooper Objective Insights, Inc.

IBC: International Pharmaceutical Pricing Congress New Orleans, LA February 2-3, 1995





- * What are the Economics and Ethics of Pricing Across Countries?
- Should Pharmaceuticals be Priced Within a Narrow Band Worldwide?





- **♦ U.S. Prices** ≠ Rest of World
- Set of the set of t
- Set of the Explain This



Efforts to Show This:

- ***** GAO Reports
 - Companies Typically Charge More in the U.S. Than in the U.K.
 - Companies Typically Charge More in the U.S. Than in Canada



Efforts to Explain This:

- PMA Argument: No. of Hours Worked the Same
- * Japan Antivirals 2-7 Times U.S. Price
- What Price?
 - Direct Price?
 - Average Wholesalers Price?
 - Retail Price?



Same Price In All Countries?

- Inflation
- Currency Exchange Rates
- Price Controls
- Price Decreases
- Taxes
- Import/Export Restrictions
- Political Changes
- Health Care Structure
- Patent Expiration Dates
- Patent Law Changes
- Negotiated Prices
- Piracy



Headlines

- Pricing chaos in Italy
 - Threatened a 10% price cut
- Italian pricing borders on farce
 - No one seems sure new system still in effect
- Italian budget proposes new price cut
 - No 10% across-the-board price cut; 3-12% price cut instead
- Major product price cut in France
 - Gov't cut prices of 7 major drugs; volume sales too high
- Pakistan seeks new price formula
 - Take into account world prices for raw materials
- South African pricing system set to change
 - Possibility of changing to cost plus or net pricing
- U.S. firms lash out at Italian price cut
 - Higher the sales, higher the cut
- French Price Wrangle Continues



Pricing the Same Worldwide

- It is Irrelevant!
- Drugs Should Not be Priced the Same Across Countries
- Prices Appropriate for Each Market (Micropricing)



What is a Price?

- Free Speech
- Price is Transfer Point
- Transfer of Physical, Material Wealth
 - \$, £, ¥ For Product
 - By the Owners of the Wealth



Ethics and Society's Stake

Soth Parties Gain

- "Gain cannot be made without some other person's loss."
 - Publilius Syrus
- Positive-Sum System
- ***** Society Benefits:
 - Consumer and Producer Surpluses
- Pharmaceuticals
 - Reduce Morbidity and Mortality
 - Improve Quality of Life
 - Save Money



Ability To Pay ≥ Willingness To Pay

- Some Things Are Beyond The Limits of Our Wealth
- * Many Things Are Not



Example: HSV, CMV, and Stroke

- Different Formulations of Aciclovir
 - 38-41% of use is topical in Italy & U.K.
 - Not available in Japan
 - U.S. and European formulations different
- Different Ways of Treating HSV
 - More severe patients treated in U.S.
 - Cold sores and mild genital herpes in Germany & U.K.
- **CMV Retinitis:**
 - Ganciclovir has >80% of uses in U.S.
 - Ganciclovir has <50% of uses in France
- Stroke Prevention
 - Ticlid (Ticlopidine) sells \$40 in U.S. and \$300 in Japan



Health Care Differences

- 9,000 British Patients a Year Die Because no Kidney Dialysis
- 1,379,000 Canadians on Medical Care Waiting Lists
- Russian Health Care System Close to Collapse
 - Male life expectancy has fallen to 14 years below OECD average
 - Infant mortality up
 - More people died than were born in 1993
- Japanese Doctors Profit by Prescribing
 - Doctors prescribe and dispense
 - Patients feel cheated if few Rx's



Health Care Differences (cont.)

- Medicinal Plants Used to Treat 40% of Chinese
- Traditional Healers:
 - Apply dung to umbilical cord of newborns
 - Female circumcision
 - Don't wash hands before deliver baby or inspect wounds
- Pharmaceuticals Irrelevant to 80% in Third World



How do People, Cities, States & Countries Differ?

- Income
- Average State of Health
- Life Expectancy
- No. of Children
- No. of Telephones
- Educational Level
- Availability of Running Hot & Cold Water
- * Infrastructure



Three Scenarios

- Price Same Worldwide and Price High
- Price Same Worldwide and Price Low
- * MicroPricing: Customer-Specific Value-Based Pricing



Price Same Worldwide and Price **High**

- Price is Appropriate for Developed Countries
- ***** Price is Too High for Developing Countries
- People Cannot Afford in Developing Countries
 - Reduced Societal Wealth
 - Morbidity and Mortality



Price Same Worldwide and Price Low

- Price is Appropriate for Developing Countries
- ***** Price is a Bargain in Developed Countries
- Product May Not be Developed
 - Reduced Societal Wealth
 - Morbidity and Mortality
- Company May Not Have Resources to Develop New Products



MicroPricing: Customer-Specific Value-Based Pricing

- Price is Appropriate for Developing Countries
- * Price is Appropriate for Developed Countries
- Product Developed if Medical and Marketing Need
 - Highest Societal Wealth
 - Cost and Life-Saving Medicine



Conclusion

- Prices are Different
- It is Hard to Price the Same Worldwide
- Valid, but Irrelevant
- Price is a Transfer Point
- Exchange Helps (Almost) Everyone
- Drugs Reduce Morbidity, Mortality, and Cost
- * Value Varies Dramatically, so Should Price
- ***** Restaurants Handle Diverse People
- * Micropricing





- Handle people with dramatically different price sensitivities by offering a wide selection on the menu
- ***** Three Friends go to Dinner ...
 - One Very Poor
 - One Very Rich

